Literature DB >> 25029633

Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.

SoJeong Yi1, Hyungmi An, Howard Lee, Sangin Lee, Ichiro Ieiri, Youngjo Lee, Joo-Youn Cho, Takeshi Hirota, Masato Fukae, Kenji Yoshida, Shinichiro Nagatsuka, Miyuki Kimura, Shin Irie, Yuichi Sugiyama, Dong Wan Shin, Kyoung Soo Lim, Jae-Yong Chung, Kyung-Sang Yu, In-Jin Jang.   

Abstract

BACKGROUND: Interethnic differences in genetic polymorphism in genes encoding drug-metabolizing enzymes and transporters are one of the major factors that cause ethnic differences in drug response. This study aimed to investigate genetic polymorphisms in genes involved in drug metabolism, transport, and excretion among Korean, Japanese, and Chinese populations, the three major East Asian ethnic groups.
METHODS: The frequencies of 1936 variants representing 225 genes encoding drug-metabolizing enzymes and transporters were determined from 786 healthy participants (448 Korean, 208 Japanese, and 130 Chinese) using the Affymetrix Drug-Metabolizing Enzymes and Transporters Plus microarray. To compare allele or genotype frequencies in the high-dimensional data among the three East Asian ethnic groups, multiple testing, principal component analysis (PCA), and regularized multinomial logit model through least absolute shrinkage and selection operator were used.
RESULTS: On microarray analysis, 1071 of 1936 variants (>50% of markers) were found to be monomorphic. In a large number of genetic variants, the fixation index and Pearson's correlation coefficient of minor allele frequencies were less than 0.034 and greater than 0.95, respectively, among the three ethnic groups. PCA identified 47 genetic variants with multiple testing, but was unable to discriminate ethnic groups by the first three components. Multinomial least absolute shrinkage and selection operator analysis identified 269 genetic variants that showed different frequencies among the three ethnic groups. However, none of those variants distinguished between the three ethnic groups during subsequent PCA.
CONCLUSION: Korean, Japanese, and Chinese populations are not pharmacogenetically distant from one another, at least with regard to drug disposition, metabolism, and elimination.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25029633     DOI: 10.1097/FPC.0000000000000075

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  7 in total

1.  Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations.

Authors:  Vanessa Gonzalez-Covarrubias; José Jaime Martínez-Magaña; Regina Coronado-Sosa; Beatriz Villegas-Torres; Alma D Genis-Mendoza; Pablo Canales-Herrerias; Humberto Nicolini; Xavier Soberón
Journal:  Pharm Res       Date:  2016-07-07       Impact factor: 4.200

2.  A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform.

Authors:  Y Choi; F Jiang; H An; H J Park; J H Choi; H Lee
Journal:  Pharmacogenomics J       Date:  2016-02-16       Impact factor: 3.550

3.  Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy.

Authors:  Zhongjian Xie; Yun Chen; Sirel Gurbuz; Bin Zhang; Yujie Li; Fan Bai; Yu Chen
Journal:  Clin Interv Aging       Date:  2019-05-27       Impact factor: 4.458

4.  Single nucleotide and structural variants of CYP2D6 gene in Kinh Vietnamese population.

Authors:  Ha Hai Nguyen; Thuong Thi Huyen Ma; Nhung Phuong Vu; Quynh Thi Nhu Bach; Thang Hong Vu; Ton Dang Nguyen; Hai Van Nong
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.

Authors:  Yun Kim; Seonghae Yoon; Yewon Choi; Seo Hyun Yoon; Joo-Youn Cho; In-Jin Jang; Kyung-Sang Yu; Jae-Yong Chung
Journal:  Sci Rep       Date:  2019-12-19       Impact factor: 4.379

6.  The necessary conduct: Exploratory multiregional clinical trials in East Asia.

Authors:  Inseung Jeon; Yu Kyong Kim; Ildae Song; Deok Yong Yoon; Ki Young Huh; Xuanyou Jin; Kyung-Sang Yu; SeungHwan Lee; Yuji Kumagai; In-Jin Jang
Journal:  Clin Transl Sci       Date:  2021-08-16       Impact factor: 4.689

7.  Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity.

Authors:  Jaeseong Oh; Sojeong Yi; Namyi Gu; Dongseong Shin; Kyung-Sang Yu; Seo Hyun Yoon; Joo-Youn Cho; In-Jin Jang
Journal:  Genomics Inform       Date:  2018-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.